[Liquid biopsy in oncology: A consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].

Biopsia líquida en oncología: Consenso de la Sociedad Española de Oncología Médica (SEOM) y la Sociedad Española de Anatomía Patológica (SEAP).
Biopsia líquida CtDNA Genomic profiling Liquid biopsy Medicina de precisión Oncology Oncología Perfil genómico Precision medicine ctADN

Journal

Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia
ISSN: 1988-561X
Titre abrégé: Rev Esp Patol
Pays: Spain
ID NLM: 100885154

Informations de publication

Date de publication:
Historique:
received: 27 09 2019
revised: 27 11 2019
accepted: 09 12 2019
entrez: 5 10 2020
pubmed: 6 10 2020
medline: 6 10 2021
Statut: ppublish

Résumé

The proportion of cancer patients with tumours that harbour a potentially targetable genomic alteration is increasing considerably. The diagnosis of these genomic alterations can lead to tailoring of treatment, at the onset of disease or during progression, as well as providing additional, predictive information on the efficacy of immunotherapy. However, in up to 25% of cases, the initial tissue biopsy is inadequate for precision oncology and, in many cases, tumour genomic profiling at progression is not possible due to technical limitations of obtaining new tumour tissue specimens. Efficient diagnostic alternatives are therefore required for molecular stratification, such as liquid biopsy. This technique enables the evaluation of the tumour genomic profile dynamically and as well as capturing intra-patient genomic heterogeneity. To date, there are several diagnostic techniques available for use in liquid biopsy, each with different precision and performance levels. The objective of this consensus statement of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) is to evaluate the viability and effectiveness of the different methodological approaches of liquid biopsy in cancer patients, and the potential application of this method to current clinical practice. The experts contributing to this consensus statement agree that, according to current evidence, liquid biopsy is an acceptable alternative to tumour tissue biopsy for the study of biomarkers in various clinical settings. It is therefore important to standardise pre-analytical and analytical procedures to ensure reproducibility and to generate structured and accessible clinical reports. It is essential to appoint multidisciplinary tumour molecular committees to oversee these processes and to enable the most suitable therapeutic decisions for each patient according to the genomic profile.

Identifiants

pubmed: 33012494
pii: S1699-8855(20)30014-3
doi: 10.1016/j.patol.2019.12.001
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Practice Guideline Review

Langues

spa

Sous-ensembles de citation

IM

Pagination

234-245

Informations de copyright

Copyright © 2020 Sociedad Española de Anatomía Patológica. Publicado por Elsevier España, S.L.U. All rights reserved.

Auteurs

Ramiro Álvarez-Alegret (R)

Departamento de Patología, Hospital Universitario Miguel Servet, Zaragoza, España. Electronic address: ralvarezal@gmail.com.

Federico Rojo Todo (F)

Departamento de Patología, Fundación Universitaria Jiménez Díaz, CIBERONC, Madrid, España.

Pilar Garrido (P)

Universidad de Alcalá; Departamento de Oncología Médica, IRYCIS, Hospital Universitario Ramón y Cajal, CIBERONC, Madrid, España.

Beatriz Bellosillo (B)

Departamento de Patología, Hospital del Mar, CIBERONC, Barcelona, España.

Álvaro Rodríguez-Lescure (Á)

Departamento de Oncología Médica, Hospital General Universitario de Elche y Vega Baja, GEICAM, Elche, España.

José Luis Rodríguez-Peralto (JL)

Departamento de Patología, Hospital Universitario Doce de Octubre, CIBERONC, Madrid, España.

Ruth Vera (R)

Departamento de Oncología Médica, Complejo Hospitalario de Navarra, Navarra Institute for health research (IdiSNA), Pamplona, España.

Enrique de Álava (E)

Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, CIBERONC, Departamento de Citología e Histología Normal y Patológica, Sevilla, España.

Rosario García-Campelo (R)

Departamento de Oncología Médica, Complexo Hospitalario Universitario A Coruña, A Coruña, España.

Jordi Remon (J)

Departamento de Oncología Médica, Centro Integral Oncológico Clara Campal Barcelona (CIOCCB), HM Delfos, Barcelona, España.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH